selective IgG immunodeficiency

Summary

selective IgG immunodeficiency (MONDO:0045045) is a disease and 7 clinical trials. A subtype of dysgammaglobulinemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	selective IgG immunodeficiency
Mondo ID	MONDO:0045045
NCIT	C27142
SNOMED CT	12631000119106
UMLS	C4520847
MedGen	1618515
GARD	0025936
Is cancer (heuristic)	no

Also known as: IgG deficiency · IgG subclass deficiency · selective IgG immunodeficiency

Disease family

This is a subtype of dysgammaglobulinemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › inborn error of immunity › B cell deficiency › selective immunoglobulin deficiency disease › dysgammaglobulinemia › selective IgG immunodeficiency

Related subtypes (3): selective IgA deficiency disease, selective IgE deficiency disease, selective IgM deficiency

Subtypes (1): selective IgG subclass deficiency

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	3
PHASE2	2
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00522821	PHASE4	COMPLETED	Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
NCT00168012	PHASE3	COMPLETED	Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
NCT00168025	PHASE3	COMPLETED	Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT00322556	PHASE3	COMPLETED	Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT00417573	PHASE2	COMPLETED	Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections
NCT01847781	PHASE2	COMPLETED	PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency
NCT06355323	Not specified	COMPLETED	Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France